The present invention relates to a novel peptide for promoting cellular internalization and uses for promoting cellular internalization of a cargo and delivering the cargo using same. In addition, the present invention relates to an adjuvant and a pharmaceutical composition for preventing or treating cancer, comprising the novel peptide for promoting cellular internalization. The peptide for promoting cellular internalization according to the present invention can bind to a cargo and promote cellular internalization and intracellular delivery of the cargo, thereby enhancing the beneficial activity of the cargo. Accordingly, the peptide for promoting cellular internalization according to the present invention can be widely utilized as a drug delivery carrier and in the development of pharmaceuticals.
The present disclosure relates to natriuretic peptide analogues with enhanced stability and a pharmaceutical composition comprising the same. A C-type natriuretic peptide analogue according to an embodiment of the present disclosure exhibits a prolonged in vivo half-life, high bioavailability, and a high bone growth rate, and also has a relatively short sequence length, thereby providing advantages in that sequence synthesis is easy and production costs can be reduced. Accordingly, the analogue is expected to be effectively used in compositions for promoting growth and in the prevention or treatment of bone-related diseases.
The present invention relates to: an immuno-oncology composition comprising an anti-MUC1 antibody or an antigen-binding fragment thereof that specifically binds to a polypeptide comprising the C-terminal extracellular domain of Mucin 1 (MUC1); and a use for inducing an immuno-oncology response in a subject by using same. The anti-MUC1 antibody or antigen-binding fragment thereof that specifically binds to a polypeptide comprising the C-terminal extracellular domain of MUC1 according to the present invention does not exhibit direct cytotoxicity to cancer cells, induces an increase in the activity of immune cells, and exhibits antibody-dependent cellular cytotoxicity (ADCC) by inhibiting immune evasion of cancer. Therefore, the anti-MUC1 antibody or antigen-binding fragment thereof can be used as various types of immuno-oncology agents, immuno-oncology adjuvants, or combination therapeutic agents for inducing an immune response in a subject and enhancing an anticancer effect.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A sustained-release formulation with an increased initial burstaccording to the present disclosure exhibits a rapid release within 24 hours after administration and can exhibit a continuous sustained-release effect thereafter, thereby achieving long-term drug efficacy persistence and an initial rapid release purpose at the same time. The sustained-release formulation comprising microspheres containing leuprorelin according to the present disclosure was found to have excellent bioavailability and be safe in the human body, and thus can be effectively and safely used for the treatment of various luteinizing hormone-releasing hormone-related diseases such as endometriosis, uterine myoma, prostate cancer, pre-menopausal breast cancer, and central precocious puberty.
The present invention relates to a sustained-release microsphere containing a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof and a sustained-release formulation. More specifically, the present invention relates to a sustained-release formulation comprising a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof, wherein the formulation includes a sustained-release microsphere containing the GLP-1 receptor agonist or the pharmaceutically acceptable salt thereof, one type of low-viscosity PLGA with an intrinsic viscosity of 0.14 to 0.24 dL/g, and two or more types of high-viscosity PLGA with an intrinsic viscosity of 0.32 to 0.60 dL/g and is free of problems associated with initial burst release and delayed release, thus enabling prolonged drug release and excellent bioavailability.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical agents affecting sensory organs; pharmaceutical agents affecting metabolism; pharmaceutical agents affecting peripheral nervous system; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; allergy medications; biological preparations for medical or veterinary purposes for the treatment of central precocious puberty, endometriosis, uterine fibroids, prostate cancer and breast cancer; drugs for medical purposes for the treatment of central precocious puberty, endometriosis, uterine fibroids, prostate cancer and breast cancer; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for treatment of respiratory organs
The present invention relates to natriuretic peptide analogues with enhanced stability and a pharmaceutical composition comprising same. Exhibiting a prolonged in vivo half-life, high bioavailability, and a high bone growth rate as well as being relatively short sequence length, a C-type natriuretic peptide analogue according to an embodiment of the present invention has advantages of being easy to synthesize and reducing production costs, and thus is expected to be effectively used in compositions for promoting growth and in the prevention or treatment of bone-related diseases.
The sustained release formulation with an increased initial release amount according to the present invention exhibits a rapid release effect within 24 hours after administration and can exhibit a continuous sustained release effect thereafter, thereby achieving long-term drug efficacy persistence and an initial rapid release purpose at the same time. Found to have excellent bioavailability and be safe in the human body, the sustained-release formulation comprising microspheres containing leuprorelin according to the present invention thus can be effectively and safely used for the treatment of various luteinizing hormone-releasing hormone-related diseases such as endometriosis, uterine myoma, prostate cancer, pulmonary pre-menopausal cancer, and central precocious puberty.
The present invention relates to a novel antibody and a use thereof, and more specifically, to: an antibody-drug conjugate or a bispecific antibody comprising the antibody produced by substituting an existing antibody sequence or an antigen-binding fragment thereof, wherein the antibody does not have any glycation-related substances generated in a production process; a pharmaceutical composition comprising the antibody-drug conjugate or bispecific antibody for preventing or treating cancer; a nucleic acid encoding the antibody or an antigen-binding fragment thereof; a vector and a host cell comprising the nucleic acid; and a method for preparing an antibody or an antigen-binding fragment thereof.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
11.
Sustained release formulation composition comprising semaglutide or pharmaceutically acceptable salt thereof
The present invention relates to sustained-release microspheres which include semaglutide or a pharmaceutically acceptable salt thereof, and a sustained-release formulation composition including the same, which enable long-term sustained release of a drug without an initial burst, and have no release delay (lag phase) while having excellent bioavailability.
The present invention relates to a sustained-release microsphere containing a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof and a sustained-release formulation. More specifically, the present invention relates to a sustained release formulation comprising a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof, wherein the formulation includes sustained release microsphere containing the GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof, one type of low-viscosity PLGA with an intrinsic viscosity of 0.14 to 0.24 dL/g, and two or more types of high-viscosity PLGA with an intrinsic viscosity of 0.32 to 0.60 dL/g and is free of problems associated with initial burst release and delayed release, thus enabling prolonged drug release and excellent bioavailability.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
13.
Antibody binding specifically to MUC1 and use thereof
The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody, a pharmaceutical composition for prevention or treatment of cancer, comprising the same antibody, conjugate or bispecific antibody, and a nucleic acid encoding the same antibody, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, the antibody shows outstanding affinity and binding force to MUC1 and the antibody-drug conjugate can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
The present invention relates to a novel antibody and a use thereof, and more specifically, to: an antibody-drug conjugate or a bispecific antibody comprising the antibody or an antigen-binding fragment thereof, wherein the antibody does not have any glycation-related substances generated in a production process by substituting an existing antibody sequence; a pharmaceutical composition containing the antibody-drug conjugate or bispecific antibody for preventing or treating cancer; a nucleic acid encoding the antibody or antigen-binding fragment thereof; a vector and a host cell comprising the nucleic acid; and a method for preparing an antibody or an antigen-binding fragment thereof.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
The present invention relates to a novel antibody and a use thereof, and more specifically, to: an antibody-drug conjugate or a bispecific antibody comprising the antibody or an antigen-binding fragment thereof, wherein the antibody does not have any glycation-related substances generated in a production process by substituting an existing antibody sequence; a pharmaceutical composition containing the antibody-drug conjugate or bispecific antibody for preventing or treating cancer; a nucleic acid encoding the antibody or antigen-binding fragment thereof; a vector and a host cell comprising the nucleic acid; and a method for preparing an antibody or an antigen-binding fragment thereof.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody, a pharmaceutical composition for prevention or treatment of cancer, comprising the same antibody, conjugate or bispecific antibody, and a nucleic acid encoding the same antibody, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, the antibody shows outstanding affinity and binding force to MUC1 and the antibody-drug conjugate can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
17.
SUSTAINED RELEASE FORMULATION COMPOSITION COMPRISING SEMAGLUTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
The present invention relates to sustained-release microspheres which include semaglutide or a pharmaceutically acceptable salt thereof, and a sustained-release formulation composition including the same, which enable long-term sustained release of a drug without an initial burst, and have no release delay (lag phase) while having excellent bioavailability.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
18.
SUSTAINED RELEASE FORMULATION COMPOSITION COMPRISING SEMAGLUTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
The present invention relates to sustained-release microspheres containing semaglutide or a pharmaceutically acceptable salt thereof and a sustained-release formulation composition comprising same, which enable long-term sustained release of the drug without an initial burst, have no lag phase and have excellent bioavailability.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
19.
Pharmaceutical composition for treating levodopa-induced dyskinesia or for suppressing progression thereof
A GLP-1 receptor agonist has effects of reducing serious side effects due to long-term use of levodopa when administered in combination with levodopa, and also effects of alleviating or improving abnormal involuntary movements (AIMs) caused by levodopa. A method for prevention or treatment of levodopa-induced dyskinesia according to an embodiment of the present disclosure includes administering a glucagon-like peptide-1 (GLP-1) receptor agonist to a patient.
The USA, as represented by the Secretary, Department of Health and Human Services (USA)
Peptron, Inc. (USA)
Inventeur(s)
Kim, Dong Seok
Kim, Hee Kyung
Greig, Nigel H.
Abrégé
The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject. The method includes administering to the systemic blood circulation of the subject a therapeutically effective amount of a neuroprotective polypeptide by a controlled-release formulation or a device providing a sustained release of the neuroprotective polypeptide including at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analogue; the neuroprotective polypeptide binds to and activates a receptor that binds at least one of GLP-1, exendin-4, or a combination thereof; and the controlled-release neuroprotective formulation or the sustained release of the neuroprotective polypeptide enhances the delivery of the neuroprotective polypeptide across a blood-brain barrier (BBB) of the subject to at least a portion of the CNS relative to a rapid release formulation of the neuroprotective polypeptide. Also disclosed is a method of treating a subject with a CNS-related disease or reducing at least one symptom of a CNS-related disease in a subject in need thereof.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 25/30 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance
The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) or an antigen-binding fragment thereof, an antibody-drug conjugate comprising the antibody or the antigen-binding fragment thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the conjugate. According to the present invention, the antibody shows outstanding affinity and binding force to MUC1 and the antibody-drug conjugate in which the antibody or the antigen-binding fragment thereof is conjugated with a drug can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
The present invention relates to a pharmaceutical composition for treatment or prevention of levodopa-induced dyskinesia. When administered in combination with levodopa, the GLP-1 receptor agonist or a controlled release formulation thereof according to the present invention exhibits the effects of decreasing serious side effects caused by long-term administration of levodopa and reducing levodopa-induced, non-spontaneous dyskinesia.
The present invention relates to a pharmaceutical composition for treatment or prevention of levodopa-induced dyskinesia. When administered in combination with levodopa, the GLP-1 receptor agonist or a controlled release formulation thereof according to the present invention exhibits the effects of decreasing serious side effects caused by long-term administration of levodopa and reducing levodopa-induced, non-spontaneous dyskinesia.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61P 25/14 - Médicaments pour le traitement des troubles du système nerveux pour traiter les mouvements anormaux, p. ex. chorée, dyskinésie
24.
Antibody binding specifically to MUC1 and use thereof
The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody, a pharmaceutical composition for prevention or treatment of cancer, comprising the same antibody, conjugate or bispecific antibody, and a nucleic acid encoding the same antibody, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, the antibody shows outstanding affinity and binding force to MUC1 and the antibody-drug conjugate can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody, a pharmaceutical composition for prevention or treatment of cancer, comprising the same antibody, conjugate or bispecific antibody, and a nucleic acid encoding the same antibody, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, the antibody shows outstanding affinity and binding force to MUC1 and the antibody-drug conjugate can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUCl-related disease, for example, cancer.
The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) and a use thereof and, more particularly, to an anti-MUC1 antibody or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody or an antigen-binding fragment thereof, a pharmaceutical composition for prevention or treatment of cancer, comprising the same conjugate or bispecific antibody, and a nucleic acid encoding the same antibody or an antigen-binding fragment thereof, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, an antibody binding specifically to MUC1 or an antigen-binding fragment thereof shows outstanding affinity and binding force to MUC1 and an antibody-drug conjugate in which the antibody or an antigen-binding fragment thereof is conjugated with a drug can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMEN (USA)
PEPTRON, INC. (République de Corée)
Inventeur(s)
Kim, Dong Seok
Kim, Hee Kyung
Greig, Nigel H.
Abrégé
The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject. The method includes administering to the systemic blood circulation of the subject a therapeutically effective amount of a neuroprotective polypeptide by a controlled-release formulation or a device providing a sustained release of the neuroprotective polypeptide including at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analogue; the neuroprotective polypeptide binds to and activates a receptor that binds at least one of GLP-1, exendin-4, or a combination thereof; and the controlled-release neuroprotective formulation or the sustained release of the neuroprotective polypeptide enhances the delivery of the neuroprotective polypeptide across a blood-brain barrier (BBB) of the subject to at least a portion of the CNS relative to a rapid release formulation of the neuroprotective polypeptide. Also disclosed is a method of treating a subject with a CNS-related disease or reducing at least one symptom of a CNS-related disease in a subject in need thereof.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
28.
METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (USA)
Inventeur(s)
Kim, Dong, Seok
Kim, Hee, Kyung
Greig, Nigel, H.
Abrégé
The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject. The method includes administering to the systemic blood circulation of the subject a therapeutically effective amount of a neuroprotective polypeptide by a controlled-release formulation or a device providing a sustained release of the neuroprotective polypeptide including at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analogue; the neuroprotective polypeptide binds to and activates a receptor that binds at least one of GLP-1, exendin-4, or a combination thereof; and the controlled-release neuroprotective formulation or the sustained release of the neuroprotective polypeptide enhances the delivery of the neuroprotective polypeptide across a blood-brain barrier (BBB) of the subject to at least a portion of the CNS relative to a rapid release formulation of the neuroprotective polypeptide. Also disclosed is a method of treating a subject with a CNS-related disease or reducing at least one symptom of a CNS-related disease in a subject in need thereof.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
29.
MULTIFUNCTIONAL SKIN-PERMEATING PEPTIDE HAVING WHITENING, SKIN ELASTICITY, WRINKLE IMPROVEMENT, AND WOUND HEALING ACTIVITIES
The present invention relates to a multifunctional peptide and use of same, the multifunctional peptide having whitening, elasticity, and wrinkle improvement effects based on a skin-permeating function, and more specifically, to a method for utilizing, as a raw ingredient in functional cosmetics and medicine, a multifunctional peptide having the effects of skin permeation, melanin production inhibition, collagen production promotion, and keratinous stem cell proliferation promotion. The multifunctional skin-permeating peptide, according to the present invention, has the characteristic of easily permeating skin and is exceptionally effective in inhibiting melanin synthesis and promoting collagen synthesis and keratinous stem cell proliferation, thus rendering the peptide useful, even independently, as cosmetics or medicine for whitening skin, improving skin elasticity, improving wrinkles, or healing wounds.
The present invention relates to a multifunctional peptide and use of same, the multifunctional peptide having whitening, elasticity, and wrinkle improvement effects based on a skin-permeating function, and more specifically, to a method for utilizing, as a raw ingredient in functional cosmetics and medicine, a multifunctional peptide having the effects of skin permeation, melanin production inhibition, collagen production promotion, and keratinous stem cell proliferation promotion. The multifunctional skin-permeating peptide, according to the present invention, has the characteristic of easily permeating skin and is exceptionally effective in inhibiting melanin synthesis and promoting collagen synthesis and keratinous stem cell proliferation, thus rendering the peptide useful, even independently, as cosmetics or medicine for whitening skin, improving skin elasticity, improving wrinkles, or healing wounds.
An ultrasonic atomizer for maintaining a constant temperature of an ultrasonic vibration generating unit by decreasing a temperature at the periphery of the ultrasonic vibration generating unit even under an environment in which the ultrasonic vibration generating unit is exposed to a high temperature is provided. The ultrasonic atomizer includes: an ultrasonic vibration generating unit which generates ultrasonic waves and atomizes a spray material; a nozzle unit; a housing; and a heat exchange unit which surrounds the ultrasonic vibration generating unit, includes a separation wall which divides the heat exchange unit into heat exchange chambers, and cools heat generated from the ultrasonic vibration generating unit, in which the heat exchange chambers include: a heating chamber; and a cooling chamber which surrounds the heating chamber, and includes a cooling space by being isolated with the heat exchange unit abutting the heating chamber between the cooling chamber and the heating chamber.
B05B 15/00 - Parties constitutives des installations ou des appareillages de pulvérisation non prévus ailleursAccessoires
B05B 17/06 - Appareils de pulvérisation ou d'atomisation de liquides ou d'autres matériaux fluides, non couverts par les autres groupes de la présente sous-classe opérant suivant des procédés particuliers utilisant des vibrations ultrasonores
F28F 13/10 - Dispositions pour modifier le transfert de chaleur, p. ex. accroissement, diminution en affectant le mode d'écoulement des sources de potentiel calorifique en communiquant un mouvement pulsatoire à l'écoulement, p. ex. par vibration acoustique
F28D 1/06 - Appareils échangeurs de chaleur comportant des ensembles de canalisations fixes pour une seule des sources de potentiel calorifique, les deux sources étant en contact chacune avec un côté de la paroi de la canalisation, dans lesquels l'autre source de potentiel calorifique est une grande masse de fluide, p. ex. radiateurs domestiques ou de moteur de voiture avec canalisations d'échange de chaleur faisant partie du réservoir contenant la masse du fluide ou lui étant fixées
F28D 7/10 - Appareils échangeurs de chaleur comportant des ensembles de canalisations tubulaires fixes pour les deux sources de potentiel calorifique, ces sources étant en contact chacune avec un côté de la paroi d'une canalisation les canalisations étant disposées l'une dans l'autre, p. ex. concentriquement
An ultrasonic atomizer for maintaining a constant temperature of an ultrasonic vibration generating unit by decreasing a temperature at the periphery of the ultrasonic vibration generating unit even under an environment in which the ultrasonic vibration generating unit is exposed to a high temperature is provided. The ultrasonic atomizer includes: an ultrasonic vibration generating unit which generates ultrasonic waves and atomizes a spray material; a nozzle unit; a heat exchange unit which cools heat generated from the ultrasonic vibration generating unit; and a housing which has heat exchange chambers, where the heat exchange chambers include: a vortex chamber which is positioned in the housing at the periphery of the ultrasonic vibration generating unit and guides a vortex flow; and a thermal insulation chamber which surrounds the vortex chamber and has a separation wall which abuts the vortex chamber, and includes an internal thermal insulation space.
B05B 17/06 - Appareils de pulvérisation ou d'atomisation de liquides ou d'autres matériaux fluides, non couverts par les autres groupes de la présente sous-classe opérant suivant des procédés particuliers utilisant des vibrations ultrasonores
F28F 13/10 - Dispositions pour modifier le transfert de chaleur, p. ex. accroissement, diminution en affectant le mode d'écoulement des sources de potentiel calorifique en communiquant un mouvement pulsatoire à l'écoulement, p. ex. par vibration acoustique
Provided is an ultrasonic atomizer capable of maintaining a set temperature of an ultrasonic vibration generation unit even in an environment in which same is exposed to high temperatures by cooling the temperature in the periphery thereof. The ultrasonic atomizer comprises: an ultrasonic vibration generation unit for generating ultrasonic waves and atomizing spray material; a nozzle unit comprising a spray fluid passageway through which the spray material moves along the central shaft penetrating the center of the ultrasonic vibration generation unit, and a nozzle tip for receiving the spray material from one end of the spray fluid passageway and spraying the spray material through the other end of the spray fluid passageway; a housing surrounding the ultrasonic vibration generation unit and having a plurality of heat-exchange chambers therein; and a heat-exchange unit, surrounding the ultrasonic vibration generation unit and comprising a barrier for separating the plurality of heat-exchange chambers, for cooling the heat generated by the ultrasonic vibration generation unit, and wherein the plurality of heat-exchange chambers comprise: a heating chamber, located in the periphery of the ultrasonic vibration generation unit in the interior of the housing, comprising a heating space; and a cooling chamber surrounding the heating chamber and distanced therefrom with the heat-exchange unit, which is in contact with the heating chamber, therebetween, and comprising a cooling space.
B05B 17/06 - Appareils de pulvérisation ou d'atomisation de liquides ou d'autres matériaux fluides, non couverts par les autres groupes de la présente sous-classe opérant suivant des procédés particuliers utilisant des vibrations ultrasonores
Provided is an ultrasonic atomizer capable of maintaining a set temperature of an ultrasonic vibration generation unit even in an environment in which same is exposed to high temperatures by cooling the temperature in the periphery thereof. The ultrasonic atomizer comprises: an ultrasonic vibration generation unit for generating ultrasonic waves and atomizing spray material; a nozzle unit comprising a spray fluid passageway through which the spray material moves along the central axis penetrating the center of the ultrasonic vibration generation unit, and a nozzle tip for receiving the spray material from one end of the spray fluid passageway and spraying the spray material through the other end of the spray fluid passageway; a heat-exchange unit, surrounding the ultrasonic vibration generation unit, for cooling the heat generated from the ultrasonic vibration generation unit; and a housing surrounding the ultrasonic vibration generation unit and the heat-exchange unit and having a plurality of heat-exchange chambers in the interior thereof, wherein the plurality of heat-exchange chambers comprise: a vortex chamber, located in the periphery of the ultrasonic vibration generation unit in the interior of the housing, for guiding the flow of a vortex flow; and an insulation chamber surrounding the vortex chamber, having a barrier in contact therewith, and comprising an inner insulating space.
B05B 17/06 - Appareils de pulvérisation ou d'atomisation de liquides ou d'autres matériaux fluides, non couverts par les autres groupes de la présente sous-classe opérant suivant des procédés particuliers utilisant des vibrations ultrasonores
